Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

This study has been terminated.

( during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns. )

Study NCT00647972 Information provided by Mylan Pharmaceuticals

First Received: March 30, 2008 Last Updated: November 19, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Primary Completion Date:	May 2003 (Final data collection date for primary outcome measure)